Norma C Gutiérrez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/399599/publications.pdf

Version: 2024-02-01

840776 1199594 13 327 11 12 citations h-index g-index papers 13 13 13 793 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 2003.	4.1	59
2	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells, 2021, 10, 336.	4.1	48
3	Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability. PLoS ONE, 2015, 10, e0121581.	2.5	44
4	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. American Journal of Pathology, 2016, 186, 2171-2182.	3.8	35
5	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clinical Cancer Research, 2017, 23, 6602-6615.	7.0	25
6	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. Journal of Hematology and Oncology, 2017, 10, 92.	17.0	23
7	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 353-366.	1.9	22
8	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 207-217.	7.0	21
9	Response to imatinib mesylate in patients with hypereosinophilic syndrome. International Journal of Hematology, 2012, 96, 320-326.	1.6	16
10	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	2.6	16
11	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
12	Genomics of Plasma Cell Leukemia. Cancers, 2022, 14, 1594.	3.7	3
13	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. Cells, 2021, 10, 559.	4.1	2